Log In
Print
BCIQ
Print
Print this Print this
 

HER2 IQFISH pharmDx test

  Manage Alerts
Collapse Summary General Information
Company Agilent Technologies Inc.
DescriptionFluorescent in situ hybridization (FISH) assay based on Dako's IQISH hybridization buffer that allows for a turnaround time of about three and a half hours
Molecular Target
Mechanism of ActionDiagnostic
Therapeutic ModalityDiagnostics
Latest Stage of DevelopmentMarketed
Standard IndicationCancer, Diagnostic
Indication DetailsAid in the assessment of patients for whom Herceptin trastuzumab is being considered; Identify patients with HER-2 positive metastatic breast cancer who may be eligible for treatment with Kadcyla ado-trastuzumab emtansine
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today